![Patrick Crutcher](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrick Crutcher
Directeur/Membre du Conseil chez
JASPER THERAPEUTICS, INC.
Fortune : 9 M $ au 30/09/2026
Profil
Patrick J.
Crutcher was the founder of Mach5 Therapeutics, Inc., founded in 2024, where the title held was Chief Executive Officer & Director from 2024 to 2026.
Mr. Crutcher is also the founder of Helicore Biopharma, Inc.,AstralBio, Inc...
Mr. Crutcher currently serves as Independent Director at Amanat Acquisition Corp.
starting in 2026 and as Director at Jasper Therapeutics, Inc. starting in 2026.
Former positions include President & Chief Executive Officer at AlmataBio, Inc., Chairman & President at Ichorion Therapeutics, Inc. from 2017 to 2018, and Chief Strategy Officer at Avalo Therapeutics, Inc. in 2019.
Education includes graduate studies at the University of California, Los Angeles and undergraduate studies at the University of Illinois.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AVALO THERAPEUTICS INC 1,02 % | 06/08/2025 | 549 467 ( 1,02 % ) | 8 M $ | 30/09/2026 |
iBio, Inc.
 iBio, Inc. Pharmaceuticals: OtherHealth Technology Engages in the development and commercialization of vaccines and therapeutic proteins 0,87 % | 30/06/2025 | 300 438 ( 0,87 % ) | 354 517 $ | 30/09/2026 |
| 10/08/2026 | 518 331 ( 1,56 % ) | 300 632 $ | 30/09/2026 | |
| 20/07/2026 | 463 452 ( 9,98 % ) | 268 802 $ | 30/09/2026 |
Postes actifs de Patrick Crutcher
| Sociétés | Poste | Début |
|---|---|---|
| JASPER THERAPEUTICS, INC. | Directeur/Membre du Conseil | 16/07/2026 |
Anciens postes connus de Patrick Crutcher
| Sociétés | Poste | Fin |
|---|---|---|
ValenzaBio, Inc.
 ValenzaBio, Inc. BiotechnologyHealth Technology Develops treatment options for patients with autoimmune and inflammatory diseases | Fondateur | 01/01/2023 |
| AVALO THERAPEUTICS, INC. | Corporate Officer/Principal | 01/11/2019 |
Ichorion Therapeutics, Inc.
 Ichorion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceutical products | Président | 01/09/2018 |
Formation de Patrick Crutcher
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
27
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
University of California, Los Angeles
 University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois
 University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Avalo Therapeutics, Inc.
 Avalo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics for patients with unmet clinical need in immunology and rare genetic diseases | Health Technology |
Ichorion Therapeutics, Inc.
Ichorion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceutical products | Health Technology |
ValenzaBio, Inc.
ValenzaBio, Inc. BiotechnologyHealth Technology Develops treatment options for patients with autoimmune and inflammatory diseases | Health Technology |
Jasper Therapeutics, Inc.
 Jasper Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company which engages in enabling cures through hematopoietic stem cell therapy | Health Technology |
